ReviewCurrent opinion in immunology2016
Targeting B cells in treatment of autoimmunity.
Review in Current opinion in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 59 citations in OpenAlex.
- Targeting mTOR in Systemic Lupus Erythematosus: From Immune Cell Dysfunction to Clinical Translation.Journal of inflammation research · 2026Review
- Common origins of autoimmune diseases and lymphoid malignancies.Trends in immunology · 2025Review
- Safety and efficacy of rituximab in refractory noninfectious uveitis and scleritis.Journal of ophthalmic inflammation and infection · 2025Article
- Rituximab in the Treatment of Non-Infectious Uveitis: A Review.Journal of inflammation research · 2024Review
- Functional significance of DNA methylation: epigenetic insights into Sjögren's syndrome.Frontiers in immunology · 2024Review
- Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis.Arthritis research & therapy · 2023Review
- Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activity.Immunology and cell biology · 2023Article
- B cell depletion in patients with rheumatoid arthritis is associated with reduced IL-1β in GCF.Clinical oral investigations · 2022Article
- Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Regnase-1 is essential for B cell homeostasis to prevent immunopathology.The Journal of experimental medicine · 2021Article
- New Perspectives on the Immunopathogenesis and Treatment of Uveitis Associated With Vogt-Koyanagi-Harada Disease.Frontiers in medicine · 2021Review
- Case Report:Frontiers in neurology · 2021Article
- High-Throughput Detection of Autoantigen-Specific B Cells Among Distinct Functional Subsets in Autoimmune Donors.Frontiers in immunology · 2021Article
- Clinical value of DNA methylation markers in autoimmune rheumatic diseases.Nature reviews. Rheumatology · 2020Review
- Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs.Immunology and cell biology · 2020Review
- Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?European journal of endocrinology · 2019Review
- Rebalancing Immune Homeostasis to Treat Autoimmune Diseases.Trends in immunology · 2019Review
- The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis.Nature immunology · 2019Article
- Discovery of Orally Active Hydroxyethylamine Based SPPL2a Inhibitors.ACS medicinal chemistry letters · 2019Article
- Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression.Diabetes · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
B cells have emerged as effective targets for therapeutic intervention in autoimmunities in which the ultimate effectors are antibodies, as well as those in which T cells are primary drivers of inflammation. Proof of this principle has come primarily from studies of the efficacy of Rituximab, an anti-CD20 mAb that depletes B cells, in various autoimmune settings. These successes have inspired efforts to develop more effective anti-CD20s tailored for specific needs, as well as biologicals and small molecules that suppress B cell function without the risks inherent in B cell depletion. Here we review the current status of B cell-targeted therapies for autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.